INmune Bio (INMB)
(Delayed Data from NSDQ)
$5.22 USD
-0.11 (-2.06%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $5.21 -0.01 (-0.19%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.22 USD
-0.11 (-2.06%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $5.21 -0.01 (-0.19%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for INmune Bio, Inc. (INMB) points to a 98.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 104.7% upside potential for INmune Bio, Inc. (INMB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
by Zacks Equity Research
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
by Zacks Equity Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.
INmune (INMB) Announces Positive Data for its AD Candidate
by Zacks Equity Research
INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.